GSK begins swine flu trials

Pharmaceutical giant GlaxoSmithKline has commenced its clinical trials in Germany in a bid to create a virus to combat the current swine flu pandemic.

Results are expected to be released next month. In a statement, GKS said,

"The first clinical trial, being conducted in Germany, will assess the use of the vaccine in healthy adults. Initial data is expected to be available for sharing with regulatory authorities in September."

The vaccine, currently called Pandemic (H1N1) 2009, is expected to be distributed over the next few weeks. Those believed to be most at risk from the virus, such as the elderly and children, will be treated first as the vaccine is shipped to Europe, America and Canada.

GSK is among a select few leading pharmaceutical companies that are creating vaccines against the A(H1N1) virus for millions of people to take ahead of the 'flu seasons' so that they avoid contracting the illness. It is expected that up to one in five could contract the virus by the end of the year.

Like this article? Get the RSS feed: